Customized phage therapies to eradicate
harmful bacteria in chronic diseases
BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin
- Primary endpoints are safety and tolerability - Exploratory endpoints include proof of principle by measurement of C. acnes skin levels - Clinical data are expected at the end of the first quarter of 2020 Ness Ziona, Israel – Dec. 2, 2019 – BiomX Inc. (NYSE: PHGE),...
BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
- Data presented at the presidential plenary translational session of the AASLD conference - Results demonstrate in vivo use of a phage cocktail effectively eradicated a bacteria hypothesized to be a disease modifying target in Primary Sclerosing Cholangitis (PSC)...
BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director
Ness Ziona, Israel – November 4, 2019, – BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies, today announced the election of Russell G. Greig, Ph.D., as Chairman of the Board of Directors and Lynne Sullivan as Board...